Differential binding properties of oripavines at cloned μ- and δ-opioid receptors

European Journal of Pharmacology

Volumn 378, Issue 3, 1999, Pages 323-330

  Lee, Katherine O ^a   Akil, Huda ^b   Woods, James H ^a,c   Traynor, John R ^a  

^a Univ M   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Buprenorphine; Efficacy; Etorphine; Ligand binding; Opioid receptor; Oripavine

Indexed keywords

BUPRENORPHINE; DELTA OPIATE RECEPTOR; FENTANYL; KAPPA OPIATE RECEPTOR; OPIATE ANTAGONIST; OPIATE RECEPTOR; ORIPAVINE;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG COMPETITION; GLIOMA CELL; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL;

EID: 0032791257     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00460-4     Document Type: Article

References (42)

1. 35S ]thio) triphosphate binding by endogenous opioids acting at a cloned mu receptor J. Pharmacol. Exp. Ther. 286:1998;282-288.
2. Birnbaumer L., Abramovitz J., Brown A.M. Receptor-effector coupling by G proteins. Biochim. Biophys. Acta. 1031:1990;163-224.
3. Blane G.F., Boura A.L.A., Fitzgerald A.E., Lister R.E. Actions of etorphine hydrochloride, (M99): a potent morphine-like agent. Br. J. Pharmacol. 30:1967;11-22.
4. Bot G., Blake A.D., Li S., Reisine T. Mutagenesis of a single amino acid in the rat μ-opioid receptor discriminates ligand binding. J. Neurochem. 70:1998;358-365.
5. Carroll J.A., Shaw J.S., Wickenden A.D. The physiological relevance of low agonist affinity binding at opioid μ-receptors. Br. J. Pharmacol. 94:1995;625-631.
6. 50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;2745-2752.
7. Childers S.R., Snyder S.H. Differential regulation by guanine nucleotides of opiate agonist and antagonist receptor interactions. J. Neurochem. 34:1980;583-593.
8. Childers S.R., Fleming L.M., Selley D.E., McNutt R.W., Chang K.J. BW373U86: a nonpeptidic δ-opioid agonist with novel receptor-G protein-mediated actions in rat brain membranes and neuroblastoma cells. Mol. Pharmacol. 44:1993;827-834.
9. Clark M.J., Emmerson P.J., Mansour A., Akil H., Woods J.H., Portoghese P.S., Remmers A.E., Medzihradsky F. Opioid efficacy in a C6 glioma cell line stably expressing the delta opioid receptor. J. Pharmacol. Exp. Ther. 283:1997;501-510.
10. Cowan A., Doxey J.C., Harry E.J.R. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br. J. Pharmacol. 60:1977;547-554.
11. Cowan A., Lewis J.W., MacFarlane I.R. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br. J. Pharmacol. 60:1977;537-545.
12. Dewey W.L., Harris L.S. Antinociceptive activity of narcotic antagonist analgesics and antagonistic activity of narcotic analgesics in rodents. J. Pharmacol. Exp. Ther. 179:1971;652-659.
13. Dhawan B.N., Raghubir C.R., Reisine T., Bradley P.B., Portoghese P.S., Hamon M. International union of pharmacology: XII. Classification of opioid receptors. Pharmacol. Rev. 48:1996;567-592.
14. 6 glioma cell line expressing the μ opioid receptor. J. Pharmacol. Exp. Ther. 278:1996;1121-1127.
15. Hambrook, J.M., Rance, M.J., 1976. The interaction of buprenorphine with the opiate receptor: lipophilicity as a determining factor in drug-receptor kinetics. In: Kosterlitz, H.W. (Ed.), Opiates and Endogenous Opioid Peptides. Elsevier, Amsterdam, North-Holland, pp. 295-3301.
16. Ishizuka Y., Oka T. Regulation of opioid antagonist and mu, kappa or delta agonist binding by guanine nucleotide and sodium. Jpn. J. Pharmacol. 36:1984;397-405.
17. Jauzac Ph., Puget A., Meunier J.C. Physical separation of the agonist and antagonist forms of a mu opiate receptor? Life Sciences. 33:1983;195-198. Suppl. I.
18. Kamei J., Susuki T., Misawa M., Nagase H., Kasuya Y. Antinociceptive effect of dihydroetorphine in diabetic mice. Eur. J. Pharmacol. 275:1995;109-113.
19. Kenakin, T., 1997. Pharmacologic Analysis of Drug-receptor Interactions. Raven Press, New York, NY.
20. Klee W.A., Nirenberg F. A neuroblastoma×glioma hybrid cell line with morphine receptors. Proc. Natl. Acad. Sci. U.S.A. 71:1974;3474-3477.
21. Kong H., Raynor K., Yasuda K., Moe S.T., Portoghese P.S., Bell G.I., Reisine T. A single residue, aspartic acid 95, in the δ opioid receptor specifies selective high affinity agonist binding. J. Biol. Chem. 268:1993;23055-23058.
22. Kurose H., Katada T., Amano T., Ui M. Specific uncoupling by islet-activating protein, pertussis toxin, of negative signal transduction via α-adrenergic, cholinergic, and opiate receptors in neuroblastoma×glioma hybrid cells. J. Biol. Chem. 258:1983;4870-4875.
23. Kosterlitz H.W., Leslie F.M., Waterfield A.A. Rate of onset and offset of action of narcotic analgesics in isolated preparations. Eur. J. Pharmacol. 32:1975;10-16.
24. + and guanylyl imidodiphosphate Brain Res. 249:1982;345-352.
25. Leander J.D. Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology. 26:1987;1445-1447.
26. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
27. Medzihradsky F., Emmerson P.J., Mousigian C.A. Lipophilicity of opioids determined by a novel micromethod. J. Pharmacol. Toxicol. 27:1992;67-69.
28. Negus S.S., Dykstra L.A. Kappa antagonist properties of buprenorphine in the shock titration procedure. Eur. J. Pharmacol. 156:1988;77-86.
29. Puttfarcken P., Werling L.L., Brown S.R., Cote T.E., Cox B.M. Sodium regulation of agonist binding at opioid receptors: I. Effects of sodium replacement on binding at μ- and δ-type receptors in 7315c and NG108-15 cells and cell membranes. Mol. Pharmacol. 30:1986;81-89.
30. Richards M.L., Sadee W. In vivo receptor binding of oripavines to μ, δ, and κ-sites in rat brain as determined by an ex-vivo radiolabeling method. Eur. J. Pharmacol. 114:1985;343-353.
31. 2+ and other divalent cations on the binding of tritiated opioid ligands. J. Neurochem. 59:1992;467-472.
32. Rothman, R.B., Ni, Q., Xu, H., 1995. Buprenorphine: a review of the binding literature. In: Cowan, A., Lewis, J.W. (Eds.), Buprenorphine: Combating Drug Abuse with a Unique Opioid. Wiley-Liss, New York, NY, pp. 19-29.
33. Toll L. Comparison of mu opioid receptor binding on intact neuroblastoma cells with guinea pig brain and neuroblastoma cell membranes. J. Pharmacol. Exp. Ther. 260:1992;9-16.
34. Toll L., Berzetei-Gurske I.P., Polgar W.E., Brandt S.R., Adapa I.D., Rodriguez L., Schwartz W., Haggart D., O'Brien A., White A., Kennedy J.M., Craymer K., Farrington L., Auh J.S. Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res. Monogr. 178:1998;440-445.
35. 35S ]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells Mol. Pharmacol. 47:1995;848-854.
36. Traynor J.R., Corbett A.D., Kosterlitz H.W. Diprenorphine has agonist activity at opioid kappa-receptors in the myenteric plexus of the guinea pig ileum. Eur. J. Pharmacol. 137:1987;85-89.
37. Villiger J.W. Binding of buprenorphine to opiate receptors. Neuropharmacology. 23:1984;373-375.
38. Walker E.A., Zernig G., Young A.M. In vivo apparent affinity and efficacy estimates for opiates in a rat tail-withdrawal assay. Psychopharmacology. 136:1998;15-23.
39. Wang D.X., Lu X.Q., Qin B.Y. Dihydroetorphine is a μ receptor-selective ligand. J. Pharm. Pharmacol. 47:1995;669-673.
40. Werling L.L., Brown S.R., Puttfarcken P., Cox B.M. Sodium regulation of agonist binding at opioid receptors: II Effects of sodium replacement on opioid binding in guinea pig cortical membranes. Mol. Pharmacol. 30:1986;90-95.
41. Wong C.S., Su Y.F., Waltkins W.D., Chang K.J. Opioid agonist binding affinity is increased by magnesium in the presence of guanosine diphosphate but decreased by magnesium in the presence of guanyl-5′-yl imidodiphosphate. J. Pharmacol. Exp. Ther. 268:1994;653-661.
42. Wuster M., Costa T., Aktories K., Jakobs K.H. Sodium regulation of opioid agonist binding is potentiated by pertussis toxin. Biochem. Biophys. Res. Commun. 123:1984;1107-1115.